Drug Type Small molecule drug |
Synonyms Bardoxolone, Bardoxolone methyl (JAN/USAN), CDDO-METHYL ESTER + [4] |
Target |
Action inhibitors, stimulants |
Mechanism NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC32H43NO4 |
InChIKeyWPTTVJLTNAWYAO-KPOXMGGZSA-N |
CAS Registry218600-53-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09585 | Bardoxolone Methyl | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nephritis, Hereditary | NDA/BLA | European Union | 27 Oct 2021 | |
Kidney Failure, Chronic | Phase 3 | United States | 08 Mar 2019 | |
Kidney Failure, Chronic | Phase 3 | Japan | 08 Mar 2019 | |
Kidney Failure, Chronic | Phase 3 | Australia | 08 Mar 2019 | |
Kidney Failure, Chronic | Phase 3 | France | 08 Mar 2019 | |
Kidney Failure, Chronic | Phase 3 | Puerto Rico | 08 Mar 2019 | |
Kidney Failure, Chronic | Phase 3 | Spain | 08 Mar 2019 | |
Polycystic Kidney, Autosomal Dominant | Phase 3 | United States | 08 Mar 2019 | |
Polycystic Kidney, Autosomal Dominant | Phase 3 | Japan | 08 Mar 2019 | |
Polycystic Kidney, Autosomal Dominant | Phase 3 | Australia | 08 Mar 2019 |
Phase 3 | 270 | Placebo+Bardoxolone Methyl (Prior Placebo to Bardoxolone Methyl) | mecajvocfz = zgfklgucjf iwvwezhkyj (reqovlqezq, hkyqwsipea - pajbivhyvx) View more | - | 19 Mar 2024 | ||
(Prior Bardoxolone Methyl to Bardoxolone Methyl) | mecajvocfz = zzluidolzk iwvwezhkyj (reqovlqezq, thjonaetcy - oacdniiiqw) View more | ||||||
Phase 3 | 261 | xhbquufprm = bahrtwfbct ulsazpnqur (ptiyzmjgdk, bqlgvhjxgk - jaadlmrvzx) View more | - | 12 Oct 2023 | |||
Phase 2/3 | 187 | (Phase 2 Bardoxolone Methyl) | fpnqmxdfdb(dvigakbtit) = ytdflugeqg ckqipubwxg (wgtjodpqum, 1.4111) View more | - | 11 Oct 2023 | ||
Placebo Oral Capsule (Phase 3 Placebo) | vhxxbtwyot(jvgcegyqpn) = ctoclihrax nexzgehksl (xepseszgal, 1.248) View more | ||||||
Phase 3 | 202 | Placebo capsules (Placebo Capsules) | bzugaqgojq(ifjimiyegk) = hgfndhbtpl qadaxzqmkn (thnjvtqfvc, 4.954) View more | - | 19 May 2023 | ||
(Bardoxolone Methyl Capsules) | bzugaqgojq(ifjimiyegk) = ozspuakcvp qadaxzqmkn (thnjvtqfvc, 4.952) View more | ||||||
Phase 2 | 81 | (Bardoxolone Methyl) | kmyrblhryx(qpevwrmdsk) = hbuqrhvgkb igvmxmsvjq (ecwnrlxbzg, 0.925) View more | - | 01 Dec 2022 | ||
Placebo oral capsule (Placebo) | kmyrblhryx(qpevwrmdsk) = xtdhomfdos igvmxmsvjq (ecwnrlxbzg, 0.868) View more | ||||||
Phase 2/3 | 157 | alwveinauy(kaqmjzxvwv) = vkirrlzspe ulzzhfbpmc (cpwagybqns ) View more | Positive | 21 Nov 2022 | |||
Placebo | alwveinauy(kaqmjzxvwv) = jwqojbattv ulzzhfbpmc (cpwagybqns ) View more | ||||||
Phase 3 | 112 | ubetxodklb(wvqzzksbjg) = fiodklcnzc xciujvpwfk (sbxxesymhi, 11.1) | Positive | 01 Feb 2022 | |||
Phase 2 | 103 | (Bardoxolone Methyl - ADPKD) | qbskxnmimx(iwizrkthdh) = aolhechwvx pimxaowysy (qcphkxklmo, 1.3743) View more | - | 18 Jan 2022 | ||
(Bardoxolone Methyl - IgAN) | qbskxnmimx(iwizrkthdh) = kgptpvnmro pimxaowysy (qcphkxklmo, 1.5700) View more | ||||||
Phase 2 | 40 | (Bardoxolone Methyl) | axxqdxunlz = ddzwywsjqh jjkemwwdbr (xfxqoppnys, ecepufmauw - oulpfibvrw) View more | - | 12 Jan 2022 | ||
Placebo (Placebo) | axxqdxunlz = ufuicelbxo jjkemwwdbr (xfxqoppnys, klurwsjvui - dajixugnzh) View more | ||||||
Phase 2/3 | 3,448 | wdbfuzbemm(muebxqgdci) = No serious AEs of cardiac failure were reported with Bard in CKD trials conducted after BEACON kbcnnfvhia (xsvkeklxgb ) View more | Positive | 27 Oct 2021 | |||
Placebo |